UCHL1/PGP 9.5 Dynamic in neuro-immune-cutaneous milieu : focusing on axonal nerve terminals and epidermal keratinocytes in psoriatic itch by Kupczyk, Piotr et al.
Research Article
UCHL1/PGP 9.5 Dynamic in Neuro-Immune-Cutaneous
Milieu: Focusing on Axonal Nerve Terminals and Epidermal
Keratinocytes in Psoriatic Itch
Piotr Kupczyk ,1,2 AdamReich ,3 Mariusz Gajda ,4
Marcin HoBysz,5 EdytaWysokiNska,6 Maria Paprocka,7
Dmitry Nevozhay,8,9 Grzegorz Chodaczek,10 PaweB P. JagodziNski ,5
Piotr ZióBkowski,1 and Jacek C. Szepietowski 11
1 Department of Pathomorphology, Faculty of Medicine, Silesian Piast Wroclaw Medical University, Wroclaw, Poland
2 Laboratory of Immunogenetics and Tissues Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy,
Polish Academy of Sciences, Wroclaw, Poland
3 Department of Dermatology, Institute of Experimental and Clinical Medicine, Faculty of Medicine,
University of Rzeszow, Rzeszow, Poland
4 Department of Histology, Medical Collage, Jagiellonian University, Krakow, Poland
5 Department of Biochemistry and Molecular Biology, Karol Marcinkowski Medical University of Poznan,
Poznan, Poland
6 Laboratory of Tumor Molecular Immunobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy,
Polish Academy of Sciences, Wroclaw, Poland
7 Laboratory of Glycobiology and Cell Recognitions, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy,
Polish Academy of Sciences, Wroclaw, Poland
8 School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia
9 Department of Imaging Physics, MD Anderson Cancer Center, The University of Texas,
Houston, Texas, USA
10Confocal Microscopy Laboratory, Wroclaw Research Centre EIT+, Wroclaw, Poland
11Department of Dermatology, Venereology and Allergology, Silesian Piast Wroclaw Medical University,
Wroclaw, Poland
Correspondence should be addressed to Piotr Kupczyk; piotr.kupczyk.81@gmail.com
Received 29 January 2018; Revised 28 May 2018; Accepted 7 June 2018; Published 25 July 2018
Academic Editor: Maxim E. Darvin
Copyright © 2018 Piotr Kupczyk et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Psoriasis is an immunogenetic skin disease manifesting as plaque lesions on the skin. Patients with psoriasis frequently suffer from
itch, an unpleasant sensation causing a desire to scratch. Psoriatic itch is mainly transmitted by unmyelinated C-fibers; however,
the exact molecular mechanism of psoriatic itch is still unexplained. Protein gene product 9.5 (PGP 9.5) is a panneurological
marker commonly used for analysis of peripheral peptidergic and nonpeptidergic nerves and identification of cutaneous neuro-
immune-endocrine cells. However, some studies suggested that nonneuronal cells, like keratinocytes,may also express PGP9.5.This
phenomenon might be linked with impaired axonal transport, keratinocyte injury, or dysfunctions of neuro-immune-cutaneous
connections. The aim of this study was to analyze the expression of PGP 9.5 in psoriatic skin. We observed significantly altered
density of PGP 9.5-positive axonal nerve terminals in pruritic lesional (p=0.04) and nonlesional psoriatic skin (p>0.001) compared
with controls. In contrast, no significant differences were observed between psoriatic skin without itch and controls. Furthermore,
PGP 9.5 expression by suprabasal keratinocytes (SBKs) was significantly increased in itchy skin lesions (p=0.007) compared to
skin without itch, and a positive correlation was observed between PGP 9.5 expression and itch intensity (r=0.64; p=0.02). Our
findings indicate changes in peripheral innervations and psoriatic keratinocytes, which may influence neuro-immune-cutaneous
homeostasis and modulate itch transmission.
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1. Introduction
Psoriasis is an immunogenetic skin disease, in which neu-
roinflammation is believed to be an important pathogenic
element [1]. Neuroinflammation is considered as one of the
possible mechanisms which might enhance itch perception,
an unpleasant sensation causing a desire to scratch [2, 3].The
neurobiological background of itch in psoriasis is still poorly
understood; however abnormalities in peripheral nervous
system (PNS) are considered as one of the possible mecha-
nisms [4]. Itch is mainly mediated by unmyelinated C-fibers,
which originate from dorsal root ganglion (DRG) neurons
[5]. All (peptidergic and nonpeptidergic) PNS structures
could be visualized by a neurobiological marker: protein gene
product 9.5 (PGP 9.5), one of the most abundant proteins
of central nervous system (CNS). Its quantity constitutes up
to 3–5% of the total brain protein amount [6, 7]. PGP 9.5
is a ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) with
dual hydrolase and ligase activity and molecular weight of
27 kDa, encoded by UCHL-1 gene [6, 8]. PGP 9.5 is also a
deubiquitinating enzyme (DUB) participating in posttrans-
lational protein modification by adding to and removing
ubiquitin from polyubiquitin chains [6]. Abnormalities in
recycling or prevention of ubiquitinated proteins from the
proteosomal degradation pathways are engaged in several
neuro-immune-related diseases [6, 8]. For example, the loss
of PGP 9.5 protein is linked with decreased mono-Ub pool
and results in abnormal function of postsynaptic compart-
ments in PNS terminals [9, 10]. In turn, mutations in UCHL1
gene are associated with Parkinson disease, engaged inmotor
neuron circuitry and pain-related dysfunctions [6, 11]. In
contrast, overexpression of UCHL1/PGP9.5 was documented
as protective factor, which delays progression of Alzheimer
disease [12]. Moreover, UCHL1/PGP 9.5 abnormalities were
also linked with cancers, innate and adaptive mechanisms of
immune response, axonal transport, traumatic brain injury,
and recessive general-body neurodegeneration [6, 8].
In the skin, the UCHL1/PGP 9.5 is strictly connected with
nerve terminals; however, several studies also demonstrated
its expression by neuro-immune-endocrine cells of the skin
[13]. Basal and suprabasal keratinocytes, melanocytes, and
Merkel and Langerhans cells may contain UCHL1/PGP
9.5 [13–15]. UCHL1/PGP 9.5 comes from two independent
expression sources, primarily from CNS, but secondarily
from cutaneous-derived sources, and both meet in the skin
[14–17]. Thus, UCHL1/PGP 9.5 seems to well fitful criteria of
a marker, which could identify the nonneuronal “synaptic-
like” connections proposed by Boulais and Misery [18].
Several studies demonstrated modification of PGP 9.5 axonal
nerve terminals and neuro-immune-endocrine cells in the
skin during chronic cutaneous neuroinflammation [19].
Those abnormalities provide induction of molecular changes,
which in advanced skin lesions might resemble immune-
mediated tissue injury and engage psoriatic keratinocytes in
transmission of itch [20–24].
We aimed to investigate the connection between skin
innervations in psoriatic individuals and itch sensation. We
also have tried to elaborate the potential role of UCHL1 gene
as a new neurobiological marker of itch.
2. Material
2.1. Patients. Twenty psoriatic patients (20% females and 80%
males) were included into the study. Their age ranged from
24 to 65 years (mean 44.1±12.5 years). None of the included
patients had received any local or systemic therapies for at
least three months prior to entering the study. Individuals
with other cutaneous or systemic diseases which might
interfere with study results were excluded. Patients were
divided into two groups in relation to their itch status: with
(Itch+) and without (Itch-) itch (n=14 and n=6, respectively).
The control group consisted of 20 healthy individuals (60%
females and 40% males) who underwent a routinely sched-
uled correction during plastic surgery. The age of control
group ranged from 30 to 79 years (mean 56.3±13.0 years).
All patients provided written informed consent, while study
protocol was approved by the Ethics Committee at the
Wroclaw Medical University (decision 669/2011) and was
carried out in accordance with the principles of the Helsinki
Declaration.
2.2. Reference Material. The total brain RNA (Agilent Tech-
nologies, USA) from human postmortem and human brain
hippocampus (Clontech Laboratories, USA) were used for
UCHL1 gene transcript and PGP 9.5 protein detection.
3. Methods
3.1. Clinical Parameters. Psoriasis Area Severity Index (PASI)
was used as the parameter to assess the severity of psoriasis.
The mean PASI in analyzed patients was 15.7±10.2 points
(range: 6.4–44.0 points). The Visual Analogue Scale (VAS)
scorewas used for evaluation ofmaximal itch intensity within
24 hours prior to skin biopsy (mean: 3.9±2.8 points; range:
0–8 points).
3.2. Skin Biopsies: Preservation and Fixation. The 5 mm
punch biopsies were taken fromnonlesional and lesional skin
of patients with psoriasis. Using sterile scissors biopsies were
divided and primary one was immediately preserved in RNA-
later (Qiagen, USA) solution and transferred to the -80∘C.
The second part of a biopsy was fixed in 4% paraformalde-
hyde (PFA) solution in 0.1 M phosphatase buffer saline (PBS)
for 12 hours and transferred to the 30% sucrose (POCH,
Poland) solution in 133 mM of Sörensen buffer for another
24 hours at 4∘C. After fixation, biopsies were immediately
immersed in optimum cutting temperature medium (O.C.T.,
CellPath, United Kingdom) and 15 𝜇m frozen skin sections
were prepared (Superfrost Ultra Plus, Thermo Scientific,
Germany) using cryostat (Leica, Germany) and stored at -
20∘C for further analysis.
3.3. Cell Cultures. Human immortalized keratinocyte cell
line HaCaT (ACTT, USA) were cultured in DMEM (Biow-
est, USA) growth medium supplemented with 10% FBS
(Gibco, USA) and 1% PSA (Sigma-Aldrich, USA) solution at
37∘C in a humidified atmosphere of 5% CO2 and 95% air.
Cells after 70–80% confluence were incubated with 0.05%
trypsin/EDTA (IITD PAN,Wroclaw, Poland) for 5 min., pas-
saged, seeded at 2x105density in 6-well plate, and preserved
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for further experiments. For gene expression analyses, cells
were suspended in 1 ml of Trizol (Invitrogen, USA) and
immediately transferred to -80∘C. For protein analysis, cells
were lysed using 1 ml of RIPA buffer and transferred to -20∘C.
Finally, for immunofluorescence imaging, cells were seeded
at 96-well plate and fixed in 4% PFA for 10 min. at RT and
100𝜇l of PBS per well was added before immunofluorescence
protocol.
3.4. RNA isolation and Reverse Transcription. The total RNA
was isolated from skin biopsies embedded in RNAlater
(Ambion, USA). The skin fragments were homogenized
in Trizol (Invitrogen, USA) and introduced to the Tissue
Fibrous Kit (Qiagen, USA) protocol. The DN-ase I treatment
was applied to exclude possible contaminations and prevent
hybridization of primers and probes to gDNA. Additionally,
commercially available One-Step PCR Removal Inhibitor Kit
(Zymo Research, USA) was also used for purification of RNA
from possible PCR skin inhibitors. The quality and quantity
of RNA after extraction were estimated using Nanodrop
(Eppendorf, Germany) and only samples with 260/280 nm
absorbance coefficient in the range between 1.8 and 2.1 were
further used.TheRNAsampleswere incubated for 10minutes
at 65∘C and immediately transferred on ice to minimize
formation of RNA secondary and tertiary structures before
reverse transcription. The 500 ng of total RNA was reverse
transcribed on cDNA using First-Strand cDNA Synthesis Kit
for RT-PCR (Roche, Germany).
3.5. Probe and Primer Design. Primers and probes for human
UCHL1 gene and housekeeping ACTB, as well as universal
probe library (UPL) hydrolysis probes, were designed using
ProbeFinder 2.48 (Roche, Germany) software, UCHL-1 for-
ward: CCTGAAGACAGAGCAAAATGC and reverse: TGT-
CATCTACCCGACATTGG (Genomed, Poland) with detec-
tion system ofUPL 27 probe amplified 95 nucleotide region at
the border of constitutively expressed exons (4/5). Reference
sequence for UCHL1 gene was NM 004181.4 (NCBI, USA).
3.6. Relative Gene Expression by Real-Time PCR (RT-PCR).
The RT-PCR reaction was performed in Roche LightCycler
480 II Thermocycler (Roche, Germany) in a volume of 10 𝜇l.
The reaction volume consisted of 5 𝜇l of LightCycler UPL
ProbeMaster (Roche, Germany), 0,5 𝜇M forward and reverse
primers, and 0.2 𝜇M UPL probe 27 and 1 𝜇l cDNA. The
reaction conditions were as follows: preincubation at 95∘C
by 10 min., 50 cycles of amplification step: 95∘C by 15 s for
denaturation, 58∘C by 1 min. for elongation step, and 10 s at
72∘C for detection and next the plate was cooled at 40∘C for
10 s. The relative gene expression was presented using 2-ΔΔCt
method.
3.7. Immunofluorescence. The frozen skin sections and
HaCaT fixed cells underwent the same immunofluorescence
protocol with additional preincubation step for skin frozen
sections with incubation for 10 minutes in solution of 5%
acetic acid (POCH, Poland) in PBS and blocking step for
cells and sections in blocking solution (BS): 3% bovine serum
albumin (BSA) (LabEmpire, Poland), 5% normal donkey
serum (Jackson Immunoresearch, USA), 0.05% Tween 20
(Sigma-Aldrich, Germany), and 0.01% Triton-X100 (Sigma-
Aldrich, Germany) in PBS with incubation time of 1 hour
at 4∘C. After blocking step and 3x PBS rinsing, cells and
sections were incubated with primary mouse anti-human
PGP 9.5 antibody (13C4 clone, Ultraclone, United Kingdom)
diluted in PBS (1:500) for 24 hours at 4∘C temperature.
Negative control was prepared by omitting the primary
antibody and IgG-Alexa Fluor 488 isotype control (BD
Bioscience, USA). Next day, sections were rinsed three times
in PBS for 5 min. and incubated for 2 hours at RT in dark
conditions with the secondary donkey anti-mouse Alexa
Fluor 546 H+L (A-10036, Invitrogen, USA) antibody in PBS
(dilution 1:500). In turn, donkey anti-mouse Alexa Fluor
488 H+L (A-21202, Invitrogen, USA) was used for detection
of PGP 9.5 in HaCaT cultures with the same conditions.
The immunofluorescence mounting medium with DAPI
(Invitrogen, USA) was used for nucleus counterstaining.
3.8. Western-Blot. Skin biopsies were homogenized in 400 𝜇l
of cold PBS using electric tissues homogenizer (ProScientific,
USA). After disruption, 400 𝜇l of 2X Radioimmunoprecip-
itation Assay Buffer (RIPA, 50 mMTris-HCl, 150 mMNaCl,
0.1% SDS, 1% NP-40, 0.5% DOC, and pH=8.0) was added
with proteinase cocktail inhibitor (Sigma-Aldrich,Germany).
Next, probes underwent centrifugation (15min. 10x103g, 4∘C)
and supernatants were collected. The protein concentration
was determined using a BCA Protein Assay Kit (Pierce, IL,
USA,).The 40 𝜇g of protein lysates wasmixed with Laemmli’s
loading buffer (4:1) and denatured by incubation at 95∘C
for 5 min. and immediately transferred on ice. As reference
material, the 3 𝜇g of normal human hippocampus (Clontech
Laboratories, USA) was used. The 12% SDS-PAGE gel elec-
trophoresis was performed and protein transfer was verified
by Coomassie Brilliant Blue (Sigma, USA) staining. Next,
semidry electrotransfer from gels to PVDF and Whatman
membranes (0.45𝜇m,Millipore,USA)was performed for one
hour (Bio-Rad, USA). In the next step, blotted membranes
were hydrated by rinsing 3 times for 5 min. in solution
of Tris-buffered saline with 0.05% Tween 20 (TBST) and
incubated with 1% casein solution in TBST (0.1% Tween-
20) at RT for 1 hour. Next, the primary mouse anti-human
PGP 9.5 (1:10000, Utraclone, 13C4 clone), the same antibody
used for immunofluorescence, was diluted in TBST with 1%
casein and incubated overnight at 4∘C. Rabbit polyclonal
anti-human 𝛽-actin (1𝜇g/ml, 1:2000, Cat. num.: SC-7210,
Santa Cruz Biotechnology, USA) was used as reference. Next
day, membranes were incubated with secondary antibod-
ies conjugated with horseradish peroxidase-HRP diluted in
blocking solution. Polyclonal goat anti-mouse-HRP (1:1000,
Cat. num. P0447, Dako, Denmark) was used for PGP 9.5,
while polyclonal goat anti-rabbit-HRP (1:1000, Cat. num.:
P0448, Dako, Denmark) was used for 𝛽-actin detection. The
chemiluminescence detection kit (SuperSignal West Pico
Chemiluminescent, Cat. num.: PI-34078, Thermo Scientific,
USA) was used for bands visualization.
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3.9. Image Analysis. For frozen skin sections, immunoflu-
orescence detection was carried out using the fluorescence
microscope (Zeiss, Germany) with constant exposure con-
ditions (1000 ms), microscope camera settings (Zeiss, Ger-
many) at Zeiss Vision Image (ZVI) format using AxioVision
software (Zeiss, Germany). In turn, positive immunofluores-
cence in HaCaT cells was detected and analyzed using the
scanning confocal microscopy (Zeiss, USA). All fluorescence
ZVI images were converted into the 8-bit RGB TIFF image
files and transferred to the Fiji software (Fiji, ImageJ, National
Institute of Health, Bethesda, USA).
3.10. Statistical Analysis. All statistical analyses were per-
formed using Statistica 12.0 software (Dell Software, USA).
Differences between samples from compared patient groups
were verified using Mann–Whitney U test. Correlation data
were analyzed by Spearman rank correlations test. Values of
p <0.05 were considered statistically significant.
3.11. Data Presentation. The presented graphs were per-
formed using GraphPad Prism 5.0 (GraphPad Software Inc.,
La Jolla, CA, USA), while figures were prepared by LibreOf-
fice 5.0 Software (The Document Foundation, Germany).
4. Results
Results of our investigations demonstrate cutaneous expres-
sion of UCHL1/PGP 9.5: UCHL1 gene transcript, as well as
PGP 9.5 protein expression in total skin biopsy samples. We
detect PGP 9.5 by basal (BKs) and suprabasal (SBKs) epi-
dermal keratinocytes as well as DRG axonal nerve terminals
and dermal nerve fibers, respectively (graphs and images
presented below). Furthermore, barely but stable expression
within immortalized HaCaT cells was also demonstrated
(Figure 1: (a1)–(a3), (b), and (c)). All reagents used for detec-
tion ofUCHL1 transcript andPGP9.5 proteinwere confirmed
in the human brain reference material (Figure 1(c)).
4.1. PGP 9.5 Distribution and Expression in the Skin of
Controls and Psoriasis Patients. The PGP 9.5 somatosensory
system was detectable in the skin of both healthy and
psoriatic subjects. In normal epidermis, PGP 9.5 signal was
present in axonal nerve terminals and dermal nerve fibers.
The single nerve terminals penetrating all epidermal layers
were detected only occasionally in stratum spinosum or
granulosum. We observed single nerve terminals in normal
dermis, which in some subjects crossed dermal-epidermal
border. A perivascular PGP 9.5 expression was also observed
in dermal microvascular network, sweet glands and dermal
papillae (Figure 2(a)). Furthermore, cytoplasmic expression
of PGP 9.5 was demonstrated in normal BKs and considered
as single or group arranged cells. Normal SBKs demonstrate
almost complete absence of PGP 9.5 with some barely and
heterogeneous expression via single epidermal keratinocytes
(Figure 2(a)). The nonlesional epidermis showed numerous
nerve terminals, while some of them even reached stratum
corneum, with strong expression of PGP 9.5 within BKs
(Figures 2(b) and 2(d)). In turn, PGP 9.5 expression in pso-
riatic lesions was more diversified and demonstrated gradual
expression patterns. The PGP 9.5 expression was observed in
BKs with free PGP 9.5 epidermal nerve terminals or without
detectable expression within BKs but with tendency to turn
over from weak PGP 9.5 nerve ending expression to strong
PGP 9.5 expression by SBKs. Nerve terminals in skin lesions
seemed to be more elongated in comparison to nonlesional
skin and healthy individuals (Figures 2(c) and 2(e)).
4.2. UCHL1Gene Expression in the Skin Biopsies. The expres-
sion of UCHL1 gene in skin biopsies of psoriasis patients was
downregulated in comparison to group of healthy individuals
(Figure 3(A)). UCHL1 expression in nonlesional psoriatic
skin (mean: 0.002; SD: ±0.0008, p<0.001) was significantly
lower in comparison to control group (mean: 0.008; SD:
±0.007). The psoriasis patients without itch in nonlesional
(mean: 0.001, SD: ±0.00065) and lesional skin (mean: 0.002,
SD: ±0.001) did not demonstrate significant differences of
UCHL1 expression compared with control group (mean:
0.008, SD: ±0.007). However, nonlesional skin without itch
(mean: 0.00098, SD: ±0.0007) demonstrated significantly
lower UCHL1 expression in comparison to nonlesional skin
with itch (mean: 0.0019, SD: ±0.0007, p=0.04). While skin
lesions with itch (mean: 0.0018, SD: ±0.0035) demonstrate
significantly decreased UCHL1 expression compared to con-
trol group (mean: 0.008, SD:±0.007, p=0.02), such differences
were not observed between psoriatic lesions without itch
(mean: 0.00174, SD: ±0.0016) and normal skin (mean: 0.008;
SD: ±0.007, p=0.15) (Figure 3(C)).
4.3. Density of PGP 9.5 Epidermal Nerve Terminals and Der-
mal Nerve Fibers. The numbers of epidermal PGP 9.5 axonal
nerve terminals (mean: 4.5, SD: ±1.47; p<0.001) and dermal
nerve fibers (mean: 2.53, SD: ±1.44; p<0.01) were significantly
increased in nonlesional skin of patients with psoriasis
compared to epidermis (mean: 2.6, SD: ±1.39; p<0.001) and
dermis (mean: 1.21, SD: ±0.53; p<0.01) of healthy individuals
(Figure 3(B)). In relation to psoriatic skin lesions, the number
of epidermal PGP 9.5-positive axonal nerve terminals (mean:
4.5 SD: ±4.5; p=0.07) and dermal fibers (mean: 2.1, SD:
±1.8; p=0.04) seems to be higher than their epidermal
(mean: 2.6, S.D.: ±1.4) and dermal (mean: 1.2, SD: ±0.5)
control counterparts (Figure 3(A)). In relation to itch, we
observed significantly higher number of epidermal nerve
terminals (mean: 4.93, SD: ±1.21, p<0.001) and dermal nerve
fibers (mean: 2.94, SD: ±1.21) in nonlesional skin with itch
compared to healthy subjects (mean: 1.21, SD: ±0.53; p=0.001)
(Figures 2(a) and 2(b); Figure 3(D)). We also observed
significant differences between nonlesional epidermis with
itch (mean: 4.93, SD: ±1.21) compared to nonlesional skin
without itch (mean: 3.50, SD: ±1.64; p<0.05). In turn, itchy
nonlesional dermis (mean: 2.93, SD: ±1.42) seems to have
more fibers compared to that without itch (mean: 1.58, SD:
±1.04), but the difference did not reach the statistical signifi-
cance (p=0.07) (Figures 2(b) and 2(d)). Moreover, epidermis
(mean: 5.86, SD: ±4.74) of itchy lesions, similarly to dermis
(mean: 2.56, SD: ±1.83), had higher distribution of axonal
nerve terminals and fibers compared to epidermis (mean:
1.50, SD: ±1.05; p=0.04) and dermis without itch (mean:
1.03, SD: ±1.02; p=0.07); however, statistical significance was
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(a1)
(a2)
(a3)
(b) (c)
Figure 1: Expression of UCHL1 gene and PGP 9.5 protein in skin punch biopsies, HaCaT keratinocyte cell line, and brain reference
material. Confocal scanning microcopy using HaCaT keratinocyte cell line presents images of cytoplasmatic expression of PGP 9.5 protein
(a1). Furthermore, omission of primary antibody against human PGP 9.5 (a2) as well as IgG-AF488 isotype control does not result in any
specific signal (a3). Scale bars represent 20𝜇m. UCHL1 expression at mRNA level was observed in HaCaT cell line, normal skin, and was
confirmed in brain reference material. Forward and reverse primers amplificate 95nt sequence at the border of exons 3 and 4 ofUCHL1 gene
detected using FAM-labeled UPL 27 probe. ACTB was used as housekeeping gene using VIC-labeled probe and amplificate 121nt fragment.
All amplified material was visualized using gel electrophoresis (b). Protein expression was verified using Western-blot with the same mouse
anti-human PGP 9.5 antibody and gave specific 27 kDa band in the skin, brain, and HaCaT cell line, respectively (c).
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(a)
(b)
(c)
(d)
(e)
Figure 2: PGP 9.5 distribution and expression in axonal nerve terminals and dermal nerve fibers in skin samples of healthy individuals
and nonlesional and lesional skin of psoriasis with or without itch. PGP 9.5 of epidermal axonal nerve terminals and dermal fibers in
normal healthy skin analyzed by indirect immunofluorescence staining on frozen skin sections (a). The nonlesional (b) and lesional skin (c)
with itch (Itch+), in relation to nonlesional (d) and lesional skin (e) without itch (Itch-) from psoriasis patients. Axonal nerve terminal and
dermal nerve fibers marked with red arrows. Scale bars represent 100 𝜇m.
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(B)(A)
(D)(C)
Figure 3: Graphs summarizing results of relative UCHL1 gene expression and PGP 9.5 expression within epidermal axonal nerve
terminals and dermal fibers in the skin of healthy control and psoriatic patients with division into with (Itch+) and without (Itch-)
itch. The relative expression of UCHL1 gene in psoriasis (A) and epidermal nerve fiber density (ENFD) of PGP 9.5 axonal nerve terminals
and dermal nerve fibers in nonlesional and lesional skin of psoriasis (B) along with the division into with (itch+) and without (itch-) itch
((C), (D)).
achieved only regarding the epidermis (Figures 2(c) and
2(e); Figure 3(B)). Furthermore, we observed the positive
correlation between VAS score and both PGP 9.5 epidermal
axonal nerve terminals (r=0.47; p<0.05) and number of
dermal nerve fibers (r=0.42; p<0.05) in lesional psoriatic skin
(data not shown). In addition, reverse correlation between
disease severity (PASI score) and both PGP 9.5 expression
in lesional epidermis (r=-0.51; p<0.05) and dermis (r=-0.45;
p<0.05) was also observed.
4.4. PGP 9.5 Basal (BKs) and Suprabasal (SBKs) Keratinocyte
Expression. In general, we demonstrated significantly higher
cytoplasmic expression of PGP 9.5 protein by basal (BKs)
as well as suprabasal keratinocytes (SBKs) than controls
(Figure 4). The BKs of nonlesional skin demonstrated sig-
nificantly higher expression of PGP 9.5 protein (mean: 35.1,
SD: ±22.6; p=0.001), and SBKs did (mean: 21.6, SD: ±7.0:
p=0.0001) in comparison to BKs (mean: 17.2, SD: ±3.6)
and SBKs (mean: 14.3, SD: ±2.2) of control group (Figures
4(a), 4(b), and 4(d); Figures 5(a) and 5(b)). Furthermore,
nonlesional PGP 9.5-expressing SBKs positively correlated
with VAS (SBKs: r=0.49,p=0.02), while, regarding PGP 9.5-
expressing BKs, no significant correlation with VAS was
noted (BKs: r=0.35, p=0.13). In lesional skin, significant
discrepancies of PGP 9.5 expression concerned only SBKs
(mean: 32.5, SD: ±17.2, p<0.001) when compared to controls
(mean: 14.3, SD: ±2.2) (Figure 5(b)), while psoriatic BKs
(mean: 19.2, SD: ±14.3; p=0.54) and controls (mean: 14.3, SD:
±2.2) demonstrated comparable PGP 9.5 expression (Figures
4(a), 4(c), and 4(e); Figure 5(a)). PGP 9.5 expressing SBKs
in psoriatic lesions positively correlated with itch regarding
VAS score (SBKs: r=0.64, p=0.002).The differences were also
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(a)
(b)
(c)
(d)
(e)
Figure 4: Expression of PGP 9.5 by epidermal keratinocytes in control skin and nonlesional and lesional skin with (Itch+) and without
(Itch-) itch. Immunofluorescence images of epidermal expression of PGP 9.5 in control healthy skin was found mostly in basal keratinocytes
(BKs) with weak detection by suprabasal keratinocytes (SBKs) (a). Further images represent BKs and SBKs PGP 9.5 expression in nonlesional
and lesional samples with ((b), (c); Itch+) and without ((d), (e); Itch-) itch. Inserts: western-blot analysis of PGP 9.5 expression of the
representative skin samples of two controls as well as two patients with (Itch+) and two without (Itch-) itch, respectively. Representative
bands of PGP 9.5 (27kDa) and 𝛽-actin (42kDa) endogenous control are listed in the lower right corners of merged images.
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(a) (b)
(c) (d)
Figure 5: Graphs summarizing results of semiquantitative fluorescence intensity (FI) of PGP 9.5 expression by BKs and SBKs in the
skin of healthy controls and psoriatic patients with (Itch-) and without (Itch-) itch.The semiquantitative fluorescence intensity of BKs and
SBKs in healthy control persons and nonlesional and lesional skin of psoriasis patients ((a), (c)) with (itch+) and without (itch-) itch ((b),
(d)).
observed between nonlesional BKs (mean: 26.1, SD: ±18.4;
p<0.001) compared to BKs of psoriatic lesions (mean: 18.2,
SD. ±10.38) (Figures 4(b), 4(c), 4(d), and 4(e); Figure 5(a)).
SBKs of cutaneous lesions (mean: 23.37, SD: ±15.23; p=0.007)
expressed PGP 9.5 at significantly higher level compared to
nonlesional skin (mean: 17.93, SD: ±6.34) counterparts (Fig-
ure 5(b); FI: Figures 4(c), 4(e), 4(b), and 4(d)). Furthermore,
only SBKs of itchy skin lesions (mean: 38.91, SD: ±16.72;
p=0.006) presented significantly increased expression of PGP
9.5 in comparison to lesional skin without itch (mean: 17.42,
SD: ± 3.88) (Figures 4(c) and 4(e); Figure 5(d)).
5. Discussion
Expression of UCHL1/PGP 9.5 system is observed in cells
with neuro-immune-endocrine activity and DRG neurons,
in which terminals indirectly interplay with epidermal ker-
atinocytes and are fundamental organizers of the cutaneous
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somatosensory complex [25, 26]. Experimental sciatic nerve
injury in animals demonstrated rapid downregulation of
UCHL1/PGP 9.5 expression by nerve terminals, whereas its
amounts became compensated mainly by Langerhans cells
(LCs) and Merkel cells (MCs), respectively [15, 25, 27]. How-
ever, several studies indicated that expression of PGP 9.5may
also be considered normal epidermal keratinocytes and der-
mal fibroblasts [28]. In turn, rapid induction of UCHL1/PGP
9.5 by cells of nonneuronal origin, like keratinocytes, have
been discussed and multiple scenarios were proposed [28,
29]. The keratinocytes engagement in itch-mediated signals
was proved in a number of studies using in vitro assays [26,
30]. In turn, studies from clinics demonstrated involvement
of nervous system in psoriasis, and animal models confirmed
these relations [25, 31–33]. In context of current studies,
reverse correlation between higher PGP 9.5 protein and its
lower UCHL1 gene expression was observed, with emphasis
on the lowest UCHL1 in itchy lesions. Thus, essential ques-
tion has arisen of whether decreased UCHL1 expression in
psoriasis might be linked with impaired function of neuro-
immune-cutaneous milieu. LCs impaired density is usually
observed in vivo in pain-related syndromes. Keratinocytes
and PGP 9.5+ LCs closely cooperate via direct contact with
itch-mediating PGP 9.5+, CGRP+ neurons [34]. CGRP is
a well-known cell-immunity modifier, which abolishes LCs
antigen presentation. Its increased amounts were noted to be
released from nerve terminals in psoriasis [34, 35]. Opposite
results were obtained by Sebastian et al., who demonstrated
that, in electrically induced wound injury model, expression
of UCHL1 gene and PGP 9.5 was significantly increased
at nerve terminals, but also in MCs together with other
commonly applied neuronal markers [36]. Keratinocytes in
psoriatic lesions are neuroinflammatory cells and induced
expression of other neurorelated proteins may reflect their
injured conditions [33]. Furthermore, PGP 9.5 positive
branches of DRG neurons are significantly increasing in
the presence of infiltrating cells like eosinophils, both in
vitro and in vivo in atopic dermatitis, and this mechanism
should not be negated in psoriasis [35]. In psoriasis, number
of proinflammatory mediators, such as prostaglandins, is
elevated, whereas their reactive lipid compounds contribute
to molecular modification of covalently bounded cysteine
residues in structure of PGP 9.5, e.g., in brain studies [37].
Whether inducible expression of UCHL1/PGP 9.5 system
in nonneuronal cells like keratinocytes may be a sign of
appearing molecular dysfunction and participate in trans-
mission of subjective sensations still needs to be confirmed.
However, Johansson et al. indicated that single keratinocytes
in suprabasal compartments of normal epidermis exhibit
PGP 9.5 expression [28, 29]. Inducible expression of UCHL1
was seen in vitro in primary outgrowing keratinocytes arising
from psoriasis patients, while in microdissected skin it was
only slightly elevated [38]. In turn, Eiding et al. studies
presented that UCHL1 gene was significantly increased in
nonlesional and lesional keratinocytes derived from epi-
dermis of psoriasis patients, especially in those subjected
exposed to UVB irradiation [32].The series of further studies
demonstrated that UCHL1/PGP 9.5 system may regulate
melanogenesis dependent on agouti signal protein (ASIP,
ASP in mice). ASIP is a naturally widely expressed tissue
inhibitor for melanocortin-1 receptor (MC1R) and is located
in so-called “ITCHy” locus. The locus contains principal
proteins and transcription factors responsible for skin devel-
opment. Moreover its name arises from being situated there
HECT-ITCH ligase E3 enzyme also belonging to ubiquitin
system. Its genetic knockdown results in development of non-
agouti-lethal 18H mice with spectrum of immune dysfunc-
tion andmain behavior of uncontrolled scratching of the skin
[39, 40] Melanocyte cell line treated by ASP recombinant
demonstrates rapid upregulation of UCHL1, together with
genes responsible for axonal guidance and neuronal develop-
ment [41]. Moreover, Young Seo and coworkers showed that
overexpression of UCHL1/PGP 9.5 by melanocytes resulted
in microphthalmia-associated transcription factor (MTIF)
ubiquitination and degradation, with dramatic reduction of
pigmentation [42]. MITF consists of critical protein respon-
sible for melanocytes development and melanogenesis, so it
is possible that phototherapy-induced release ofUCHL1/PGP
9.5 via melanocytes may enhance its horizontal transfer
to the neighboring keratinocytes using exosome-dependent
pathway [43]. Melanocytes in the epidermis are located in
the basal layer, while their prominent and long dendrites
penetrate to the upper epidermal compartments participat-
ing in melanin transfer to the surrounding keratinocytes
[44]. In psoriasis, melanocytes are elevated; however, MITF
expression was noted to be comparable to controls [45]. The
attention should be also focused to other studies wheremodel
of experimental skin injury demonstrated participation of
PGP 9.5 with other axonal transport factors in synaptic
cargo vesicles from DRG bodies to the periphery [46]. Thus,
whether stable expression of PGP 9.5 protein within human
epidermal keratinocytes is MITF-independent and whether
intracellular communications are engaged should be further
elucidated.
The epigenetic cytosine-phosphate-guanine (CpG) DNA
hypermethylation of UCHL1/PGP 9.5 promoter is a well-
knownmechanism responsible for partial or complete silenc-
ing of the expression within tissues and was well demon-
strated in melanoma cell lines and patients, respectively
[47]. Several studies using different spectrum of molec-
ular techniques underlined infections, oxidative stress, or
immune-mediated disorders as possible factors down- or
upregulating UCHL1/PGP 9.5 in PNS cells as well as in
nonneuronal cells [10, 48, 49]. Using siRNA technique,
UCHL1/PGP 9.5-expressing cell lines showed more than 200
downregulated and comparable number of upregulated genes
engaged in most cellular processes, also those responsible
for molecular background of psoriasis [50]. So, molecular
mechanisms of protein ubiquitination seem to be deregulated
in inflammatory-associated diseases and other ubiquitin-
related enzymes participating in signaling pathways are
analyzed to better explain their roles in psoriasis disease
[51]. Furthermore, new findings connect neurodegenerative
symptoms and neuropathic pain with activation of ubiquiti-
nation pathways; however, sensations, such as itch, are still
poorly explained in that context [11]. Increased numbers of
PGP9.5 axonal nerve terminals and dermal nerve fibers in the
skin are considered as the main itch transmitting factor and
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our data confirmed association of altered PGP 9.5 neuroepi-
dermal profile with itch. Nakamura et al. have demonstrated
that psoriasis patients have higher number of PGP 9.5
nerve terminals in the epidermis which positively correlated
with itch intensity [52]. Similar results were observed by
Takamori et al.; however, in both studies analyses were only
restricted to the diseased skin [53]. Johansson and colleagues
indicated that PGP 9.5 nerve terminals are altered only in
the skin with lesions, while nonlesional skin resembled the
samples from controls. PGP 9.5 in psoriatic lesions weremore
frequently presented on the dermal-epidermal border and
showed restricted pattern in epidermis, which is consistent
with our observations [54]. In our study, the number of
PGP 9.5 terminals in psoriatic lesions was comparable with
healthy controls; however, those in epidermis and dermis
seemed to be more elongated. In nonlesional skin, PGP
9.5 terminals were predominantly present in the epidermis.
However, patients with itch had significantly higher number
of PGP 9.5 nerve terminals in the epidermis and fibers
in the dermis in comparison to the skin without itch and
healthy control group. We also observed that number of
PGP 9.5 axonal nerve terminals in the epidermis and der-
mis of lesional skin positively correlated with VAS score.
Pergolizzi et al. demonstrated that epidermal PGP 9.5 nerve
terminals in long-established skin lesions of psoriasis may
undergo almost complete reduction.Theypostulate gradually
occurring changes in the psoriatic lesions at initial phase of
psoriasis with increased innervations and nerve projections
through all epidermal layers, to almost complete reduction
at advanced stages [55]. These results partially explained
our observations and may depend on exacerbation phase
of psoriasis [56]. The number of PGP 9.5 nerve terminals
was also recorded as increased in samples taken from scalp
of psoriatic patients; however, no relation with itch was
found [57]. The participation of C-fibers in psoriatic itch
was also confirmed by transcutaneous electrical nerve stim-
ulation, where mean of somatosensory threshold level was
significantly higher in itchy lesional skin [58]. Significantly
altered PGP 9.5 nerve terminals were observed in group of
stress exposed healthy volunteers. Acute psychoemotional
stress conditions may increase the number of cutaneous
PGP9.5 nerve terminals.Thus, decreased neuropsychological
conditions and skin neuroinflammation may also exacerbate
PNS in psoriasis [59, 60].
6. Conclusions
PGP 9.5 profiling of axonal nerve terminals in skin samples
of patients with psoriasis may constitute a useful method
for assessment of itch. In turn, our studies for the first
time indicated that increased itch-signal transmission might
be a consequence of nonneuronal synapse dysfunctions.
The interaction between nerve terminals penetrating epider-
mis and their terminations within neuro-immune-endocrine
cells in psoriasis might consist one of the possible mecha-
nisms. Thus, our findings suggest that disordered interplay
between axonal transport and epidermal keratinocytes, as
well as impaired ubiquitylation mechanisms, may constitute
a new molecular player in itch transmitting pathways.
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[17] B. Genç, A. K. B. Lagrimas, P. Kuru et al., “Visualization
of sensory neurons and their projections in an upper motor
neuron reporter line,” PLoS ONE, vol. 10, no. 7, Article ID
e0132815, 2015.
[18] M. Talagas, N. Lebonvallet, R. Leschiera, P. Marcorelles, and L.
Misery, “What about physical contacts between epidermal ker-
atinocytes and sensory neurons?” Experimental Dermatology,
vol. 27, no. 1, pp. 9–13, 2018.
[19] E. L. Foster, E. L. Simpson, L. J. Fredrikson et al., “Eosinophils
increase neuron branching in human and murine skin and in
vitro,” PLoS ONE, vol. 6, no. 7, Article ID e22029, 2011.
[20] L.-J. Zhang, G. L. Sen, N. L. Ward et al., “Antimicrobial Peptide
LL37 and MAVS Signaling Drive Interferon-𝛽 Production by
Epidermal Keratinocytes during Skin Injury,” Immunity, vol. 45,
no. 1, pp. 119–130, 2016.
[21] R. Martini andH.Willison, “Neuroinflammation in the periph-
eral nerve: Cause, modulator, or bystander in peripheral neu-
ropathies?” Glia, vol. 64, no. 4, pp. 475–486, 2016.
[22] M. Ritter-Jones, S. Najjar, and K. M. Albers, “Keratinocytes as
modulators of sensory afferent firing,” PAIN, vol. 157, no. 4, pp.
786-787, 2016.
[23] Y. Umehara, Y. Kamata, M. Tominaga, F. Niyonsaba, H. Ogawa,
and K. Takamori, “Antimicrobial peptides human LL-37 and 𝛽-
defensin-3 modulate the expression of nerve elongation factors
in human epidermal keratinocytes,” Journal of Dermatological
Science, vol. 88, no. 3, pp. 365–367, 2017.
[24] K. K. Rau, C. E. Hill, B. J. Harrison et al., “Cutaneous tissue
damage induces long-lasting nociceptive sensitization and reg-
ulation of cellular stress- and nerve injury-associated genes in
sensory neurons,” Experimental Neurology, vol. 283, pp. 413–
427, 2016.
[25] S.-T. Hsieh andW.-M. Lin, “Modulation of keratinocyte prolif-
eration by skin innervation,” Journal of Investigative Dermatol-
ogy, vol. 113, no. 4, pp. 579–586, 1999.
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